Lyka Labs Limited (LYKALABS) fair value: what the stock is really worth
As of Nov 16, 2026: fair value (intrinsic value) of Lyka Labs Limited stock ₹73.42, price ₹86.31, that is 14.9% below the price, quality 26 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Lyka Labs Limited
LYKALABS · NSEExpensive (fair value 15% below the price), weak company and price moving sideways: meets none of the 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 17, 2026.
How to read this chart
60‑month range ₹44.95 – ₹254.30 · fair‑value band ₹55.07 – ₹91.78 · the ₹86.31 price screens above the ₹73.42 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 17, 2026.
Every Wednesday you see whether Lyka Labs is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Lyka Labs Limited, a pharmaceutical company, develops, manufactures, and markets pharmaceutical formulations and active pharmaceutical ingredients in India.
Show moreShow less
The company manufactures and sells various formulations, including emollient, topical steroid, antifungal agent, topical anti-bacterial, acne management, dermatological formulation, pain killer, anti-aging, cleansing lotion, hair care, anti-dandruff shampoo, sunscreen, anti-acne, cosmeceutical, anti-oxidant tablets and combination, proton pump inhibitor, nutraceuticals, anti-malarial, anti-bacterial, corticosteroid hormones, cephalosporin, dry powder injection, anti-fungal and bacterial, bone resorption inhibitor, anti-oxidant/liver disease, antibiotic, and lyophilized products.
It also offers technical data, such as molecule stability testing data, impurity profile, and BA/BE clinical study data. The company offers its products in various forms, including injections, creams, ointments, foams, gels, and lotions. It also exports its products.
The company was incorporated in 1976 and is based in Mumbai, India.
Stock analysis
Lyka Labs Limited (LYKALABS) currently trades at ₹86.31, while our estimate is ₹73.42, 15% below the price, so the stock looks overvalued today.
Show more
Valuation
None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Scenario range: ₹55.07 (bear) to ₹91.78 (bull), the price of ₹86.31 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 26/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Lyka Labs Limited reported revenue of ₹1.3B in FY2026 versus ₹1.8B in FY2022, a compound −8.5%/yr. Reported net income was −₹100M in FY2026.
Key figures
Market cap ₹3.1B (≈ $32.8M) Micro · P/S ratio 2.09 · EPS (TTM) ₹−2.47 · Net margin −6.6% · Return on equity 2.5% · Return on assets (EBIT) 13.7% (5-year average) · Operating margin 6.0% · Revenue (TTM) ₹1.3B.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 20 out of 100 (medium confidence).
What moves the price
The share trades about 2% below its 52-week high and 92% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −15%, LYKALABS screens richer than that median.
Fair Value
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Revenue & earnings trend
Compare Lyka Labs Limited with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 848 stocks
Valuation Multiplesvs Biotechnology median · lower = cheaper
Strength profile in five axes (Snowflake)
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- P/B ratio by industry
- Net margin by industry
- Stock screener with 62 metrics
- Undervalued stocks: Indian Stocks
- Valuation of the India market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc REGN | $952.40 | $1,275 | +34% | vs LYKALABS |
| Vertex Pharmaceuticals Incorporated VRTX | $537.79 | $592.46 | +10% | vs LYKALABS |
| Samsung Biologics Co 207940 | 1,423,000 KRW | 1,552,100 KRW | +9% | vs LYKALABS |
| argenx SE ARGX | $950.95 | $908.40 | −4% | vs LYKALABS |
| CSL Limited CSL | A$199.55 | A$186.49 | −7% | vs LYKALABS |
| Moderna, Inc MRNA | $215.27 | $135.64 | −37% | vs LYKALABS |
| BeOne Medicines AG 6160 | HK$249.40 | HK$152.92 | −39% | vs LYKALABS |
| Revolution Medicines, Inc RVMD | $166.87 | $88.78 | −47% | vs LYKALABS |
| Celltrion, Inc 068270 | 214,500 KRW | 74,945 KRW | −65% | vs LYKALABS |
| Royalty Pharma plc RPRX | $68.53 | $19.01 | −72% | vs LYKALABS |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Lyka Labs Limited (LYKALABS) overvalued or undervalued?
What is the fair value of LYKALABS?
What is the quality score of LYKALABS?
What is the price target for Lyka Labs Limited (LYKALABS)?
What is the Lyka Labs Limited stock forecast for 2026?
What is the revenue of Lyka Labs Limited (LYKALABS)?
What is the intrinsic value of Lyka Labs Limited (LYKALABS)?
Is Lyka Labs Limited stock overvalued or undervalued in 2026?
Is fair value the same as the market price of LYKALABS?
How much is Lyka Labs Limited worth?
What do the bullish and bearish scenarios say about LYKALABS?
How solid is the balance sheet of Lyka Labs Limited (LYKALABS)?
How far is LYKALABS from its 52-week high?
Which stocks are comparable to Lyka Labs Limited?
Is Lyka Labs Limited stock attractive at the current price?
Is it still worth investing in stocks now?
What is the share price of Lyka Labs Limited (LYKALABS)?
What should I pay attention to with Lyka Labs Limited right now?
Key figures of Lyka Labs Limited
How large is the market capitalisation of Lyka Labs Limited (LYKALABS)?
What is the P/S ratio of Lyka Labs Limited (LYKALABS)?
What are the earnings per share of Lyka Labs Limited (LYKALABS)?
What is the net margin of Lyka Labs Limited (LYKALABS)?
What is the return on equity of Lyka Labs Limited (LYKALABS)?
What is the EBIT return on assets of Lyka Labs Limited (LYKALABS)?
What is the operating margin of Lyka Labs Limited (LYKALABS)?
How fast is revenue growing at Lyka Labs Limited (LYKALABS)?
How fast are earnings growing at Lyka Labs Limited (LYKALABS)?
How much free cash flow does Lyka Labs Limited (LYKALABS) generate?
How much net debt does Lyka Labs Limited (LYKALABS) carry?
Watch Lyka Labs Limited in the live analysis
One click puts Lyka Labs Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.